Lexicon Pharma (LXRX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 4:05 PM ESTAnnounced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe
Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024
Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP); Topline Data Expected in Q1 2025
Executed Repositioning of INPEFA® (sotagliflozin); Net Sales of $1.7 Million in Q3 2024
Conference Call and... More
